Brought to you by 
MediGene acquires NeuroVir Therapeutics in stock swap
20 Sep 2001
Executive Summary
MediGene (cardiac therapeutics and cancer vaccines) has acquired cancer therapeutics company NeuroVir Therapeutics in a stock swap. MediGene has issued about 997k new shares in exchange for the 91% of the company it did not own.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MediGene acquires NeuroVir Therapeutics in stock swap
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice